Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.Weimin Li, Robert L. Ferris, Nassim Morsli et al.|Journal of Clinical Oncology|2020Cited by 27
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.Weimin Li, Lillian L. Siu, Athena Matakidou et al.|Journal of Clinical Oncology|2020Cited by 7